PA
PBYI icon

Perceptive Advisors’s Puma Biotechnology PBYI Stock Holding History

Perceptive Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-200,000
Closed -$1.61M – 144
2018
Q1 		$1.61M Buy
200,000
+100,000
+100% +$7.49M 0.05% 96
2017
Q4 		$55K Buy
+100,000
New +$11.2M ﹤0.01% 131
2015
Q3 		– Sell
-100,000
Closed -$11.7M – 178
2015
Q2 		$11.7M Buy
+100,000
New +$18.1M 0.7% 37

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Perceptive Advisors's PBYI Position: Q3 2018 in Review

Perceptive Advisors sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 564,579 shares — an estimated $27.7M sold.

Perceptive Advisors first reported a position in PBYI in Q4 2013 and held it in 10 quarters. The position peaked at $111M in Q3 2017. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

  • Perceptive Advisors reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
  • Perceptive Advisors sold 564,579 Puma Biotechnology shares in Q3 2018, an estimated $27.7M.
  • Perceptive Advisors first reported a position in Puma Biotechnology in Q4 2013 and held it in 10 quarters.
  • Perceptive Advisors's Puma Biotechnology position peaked at $111M in Q3 2017.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.